In response to the COVID pandemic, the first clinical trial launched at SHC-VC was the ACTT-1 trial. The trial was initially brought to Stanford University's main campus in Palo Alto by the Division of Hospital Medicine and principal investigators, Dr. Kari Nadeau and Dr. Neera Ahuja. SHC Tri-Valley served as a subsite to Stanford Palo Alto. As hospitalists based at SHC Tri-Valley, Dr. David Svec, Dr. Minjoung Go and Dr. Evelyn Ling served as the sub-investigators with support from the research team at the Stanford Center for Clinical Research (SCCR).
The NIH ACTT trial was one of the first large multi-site double blinded placebo controlled trials to evaluate treatments for hospitalized patients with COVID. The first arm of the trial enrolled 1062 patients (2 at SHC Tri-Valley) and showed that remdesivir shortened time to recovery and led to the FDA approval. It has now become the standard of care treatment for hospitalized COVID patients. (see https://medicine.stanford.edu/news/current-news/standard-news/stanfordvalleycareclinicaltrial.html). Dr. Ling was featured on NPR discussing the preliminary results (https://www.npr.org/sections/health-shots/2020/04/29/848034963/antiviral-drug-remdesivir-shows-promise-for-treating-coronavirus-in-nih-study).
Since the trial structure is adaptive, it has enabled other potential therapies to also be trialed in the study. The trial has completed two subsequent arms, evaluating the drugs, barcitinib and interferon. SHC Tri-Valley has enrolled 5 and 7 patients respectively in these arms. The fourth arm of the trial was completed in early 2021 evaluating the combination remdesivir + baricitinib and remdesivir and dexamethasone.
Publications in the NEJM
ACTT1 (https://www.nejm.org/doi/full/10.1056/NEJMoa2007764)
ACTT2 (https://www.nejm.org/doi/full/10.1056/NEJMoa2031994)